WCG Unveils 2025 Trends and Insights Report: Driving Innovation and Excellence in Clinical Research
PRINCETON, N.J., Jan. 7, 2025 /PRNewswire/ -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical...
Clinical Trial
InnoGI Technologies and Bac3Gel Forge Partnership to Revolutionize Gut Microbiome Research
DELFT, Netherlands, Jan. 7, 2025 /PRNewswire/ -- InnoGI Technologies and Bac3Gel are proud to announce a groundbreaking partnership that grants...
Essex Management Appoints David Loose as Chief Executive Officer
Appointment Reflects Commitment to Continuing Essex's Strategic Vision ROCKVILLE, Md., Jan. 7, 2025 /PRNewswire/ -- Essex Management, an Emmes Group company...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco
The Keynote Address, entitled "Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD," will be presented at 10:30AM PT...
Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform
Coeptis Secures Five New Clients With Total Contract Value of $1.7 Million Dollars With More On The Horizon Signaling AI-Driven...
Ryght AI and QPS Forge Strategic Partnership to Revolutionize Global Clinical Trials
QPS Selects Ryght AI as Exclusive AI Partner for Clinical Trial Optimization and Automation while adding to Ryght's global site...
Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma
Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI).The partnership with...
ActiGraph Accelerates Clinical Trial Modernization with Transformational Acquisition of Biofourmis Life Science Business
PENSACOLA, Fla. and NASHVILLE, Tenn., Jan. 7, 2025 /PRNewswire/ -- ActiGraph, the global leader in wearable digital health technology for...
Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market
License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica...
Quris-AI’s Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation
Quris-AI to Provide Safety Assessments for Small Molecule Drug Candidates Before Initiating Clinical TrialsBOSTON and TEL-AVIV, Israel, Jan. 07, 2025...
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development...
Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial
NOVATO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human...
Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting
BOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement...
Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
* Patients in Study Reported Lower Pain Levels, Better Sleep Quality, and Improved Wellbeing * Disease Activity Score Decreased by 19.2%,...
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation• Recently reported Phase 1...
Grace Therapeutics to Participate in Upcoming Investor Events January 2025
PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace...
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need...
Study Shows 90% of Persistent Lyme Patients Excluded from Clinical Trials
Research highlights need to expand PLD eligibility criteria to reflect real world data LOS ANGELES, Jan. 7, 2025 /PRNewswire/ -- Real-world...
Senseera Raises $7.1 Million Seed Round Led by Lightspeed Venture Partners
JERUSALEM, Jan. 7, 2025 /PRNewswire/ -- Senseera, a liquid biopsy company pioneering chromatin epigenomics, announced the successful close of a...